Oncology Care Model Reduces Cost of Supportive Care Meds

The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.
Medscape Medical News